Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The multicenter European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion (CAM): thrombolysis versus conservative therapy [Multizenterstudie Der European Assessment Group for Lysis in the Eye (EAGLE) Zur Behandlung Des Zentralarterienverschlusses (ZAV): Lysetherapie Versus Konservative Therapie].

Next Previous
Trial Profile

The multicenter European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion (CAM): thrombolysis versus conservative therapy [Multizenterstudie Der European Assessment Group for Lysis in the Eye (EAGLE) Zur Behandlung Des Zentralarterienverschlusses (ZAV): Lysetherapie Versus Konservative Therapie].

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary)
  • Indications Embolism and thrombosis; Retinal vascular occlusion
  • Focus Therapeutic Use
  • Acronyms EAGLE

    • Most Recent Events

    • 25 Aug 2011 Additional trial identifiers DRKS00000088, UKF000500 identified as reported by German Clinical Trials Register.
    • 25 Aug 2011 New source identified and integrated (German Clinical Trials Register)
    • 11 Oct 2010 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top